Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease

Akio Kimura, Masao Takemura, Kuniaki Saito, Nobuaki Yoshikura, Yuichi Hayashi, Takashi Inuzuka

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background Naturally occurring autoantibodies against amyloid β (Aβ) peptide exist in the serum and cerebrospinal fluid (CSF) of healthy individuals. Recently, it was reported that administration of intravenous immunoglobulin at the mild cognitive impairment (MCI) stage of Alzheimer's disease (AD) reduces brain atrophy. Objective To examine the association between naturally occurring anti-Aβ autoantibodies and brain atrophy in patients with cognitive impairment. Methods Serum and CSF levels of anti-Aβ autoantibodies and CSF biomarkers were evaluated in 68 patients with cognitive impairment, comprising 44 patients with AD, 19 patients with amnestic MCI and five patients with non-Alzheimer's dementia. The degree of brain atrophy was assessed using the voxel-based specific regional analysis system for AD, which targets the volume of interest (VOI) in medial temporal structures, including the whole hippocampus, entorhinal cortex and amygdala. Results CSF levels of anti-Aβ autoantibodies were inversely correlated with the extent and severity of VOI atrophy, and the ratio of VOI/grey matter atrophy in patients with AD, but not in MCI or non-AD patients. Serum levels of anti-Aβ autoantibodies were not associated with these parameters in any of the patient groups. Conclusions These results indicate that CSF levels of naturally occurring anti-Aβ autoantibodies are inversely associated with the degree of the VOI atrophy in patients with AD. Although the mechanism is unclear, CSF levels of naturally occurring anti-Aβ autoantibodies may be implicated in the progression of atrophy of the whole hippocampus, entorhinal cortex and amygdala, in AD.

Original languageEnglish
Pages (from-to)126-131
Number of pages6
JournalJournal of Neurology, Neurosurgery and Psychiatry
Volume88
Issue number2
DOIs
Publication statusPublished - 01-02-2017

Fingerprint

Temporal Lobe
Amyloid
Autoantibodies
Atrophy
Alzheimer Disease
Cerebrospinal Fluid
Entorhinal Cortex
Amygdala
Hippocampus
Brain
Serum
Intravenous Immunoglobulins
Dementia
Biomarkers
Cognitive Dysfunction
Peptides

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Kimura, Akio ; Takemura, Masao ; Saito, Kuniaki ; Yoshikura, Nobuaki ; Hayashi, Yuichi ; Inuzuka, Takashi. / Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease. In: Journal of Neurology, Neurosurgery and Psychiatry. 2017 ; Vol. 88, No. 2. pp. 126-131.
@article{91087b4423444180af0a9dda3224c2e0,
title = "Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease",
abstract = "Background Naturally occurring autoantibodies against amyloid β (Aβ) peptide exist in the serum and cerebrospinal fluid (CSF) of healthy individuals. Recently, it was reported that administration of intravenous immunoglobulin at the mild cognitive impairment (MCI) stage of Alzheimer's disease (AD) reduces brain atrophy. Objective To examine the association between naturally occurring anti-Aβ autoantibodies and brain atrophy in patients with cognitive impairment. Methods Serum and CSF levels of anti-Aβ autoantibodies and CSF biomarkers were evaluated in 68 patients with cognitive impairment, comprising 44 patients with AD, 19 patients with amnestic MCI and five patients with non-Alzheimer's dementia. The degree of brain atrophy was assessed using the voxel-based specific regional analysis system for AD, which targets the volume of interest (VOI) in medial temporal structures, including the whole hippocampus, entorhinal cortex and amygdala. Results CSF levels of anti-Aβ autoantibodies were inversely correlated with the extent and severity of VOI atrophy, and the ratio of VOI/grey matter atrophy in patients with AD, but not in MCI or non-AD patients. Serum levels of anti-Aβ autoantibodies were not associated with these parameters in any of the patient groups. Conclusions These results indicate that CSF levels of naturally occurring anti-Aβ autoantibodies are inversely associated with the degree of the VOI atrophy in patients with AD. Although the mechanism is unclear, CSF levels of naturally occurring anti-Aβ autoantibodies may be implicated in the progression of atrophy of the whole hippocampus, entorhinal cortex and amygdala, in AD.",
author = "Akio Kimura and Masao Takemura and Kuniaki Saito and Nobuaki Yoshikura and Yuichi Hayashi and Takashi Inuzuka",
year = "2017",
month = "2",
day = "1",
doi = "10.1136/jnnp-2016-313476",
language = "English",
volume = "88",
pages = "126--131",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "BMJ Publishing Group",
number = "2",

}

Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease. / Kimura, Akio; Takemura, Masao; Saito, Kuniaki; Yoshikura, Nobuaki; Hayashi, Yuichi; Inuzuka, Takashi.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 88, No. 2, 01.02.2017, p. 126-131.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Association between naturally occurring anti-amyloid β autoantibodies and medial temporal lobe atrophy in Alzheimer's disease

AU - Kimura, Akio

AU - Takemura, Masao

AU - Saito, Kuniaki

AU - Yoshikura, Nobuaki

AU - Hayashi, Yuichi

AU - Inuzuka, Takashi

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Background Naturally occurring autoantibodies against amyloid β (Aβ) peptide exist in the serum and cerebrospinal fluid (CSF) of healthy individuals. Recently, it was reported that administration of intravenous immunoglobulin at the mild cognitive impairment (MCI) stage of Alzheimer's disease (AD) reduces brain atrophy. Objective To examine the association between naturally occurring anti-Aβ autoantibodies and brain atrophy in patients with cognitive impairment. Methods Serum and CSF levels of anti-Aβ autoantibodies and CSF biomarkers were evaluated in 68 patients with cognitive impairment, comprising 44 patients with AD, 19 patients with amnestic MCI and five patients with non-Alzheimer's dementia. The degree of brain atrophy was assessed using the voxel-based specific regional analysis system for AD, which targets the volume of interest (VOI) in medial temporal structures, including the whole hippocampus, entorhinal cortex and amygdala. Results CSF levels of anti-Aβ autoantibodies were inversely correlated with the extent and severity of VOI atrophy, and the ratio of VOI/grey matter atrophy in patients with AD, but not in MCI or non-AD patients. Serum levels of anti-Aβ autoantibodies were not associated with these parameters in any of the patient groups. Conclusions These results indicate that CSF levels of naturally occurring anti-Aβ autoantibodies are inversely associated with the degree of the VOI atrophy in patients with AD. Although the mechanism is unclear, CSF levels of naturally occurring anti-Aβ autoantibodies may be implicated in the progression of atrophy of the whole hippocampus, entorhinal cortex and amygdala, in AD.

AB - Background Naturally occurring autoantibodies against amyloid β (Aβ) peptide exist in the serum and cerebrospinal fluid (CSF) of healthy individuals. Recently, it was reported that administration of intravenous immunoglobulin at the mild cognitive impairment (MCI) stage of Alzheimer's disease (AD) reduces brain atrophy. Objective To examine the association between naturally occurring anti-Aβ autoantibodies and brain atrophy in patients with cognitive impairment. Methods Serum and CSF levels of anti-Aβ autoantibodies and CSF biomarkers were evaluated in 68 patients with cognitive impairment, comprising 44 patients with AD, 19 patients with amnestic MCI and five patients with non-Alzheimer's dementia. The degree of brain atrophy was assessed using the voxel-based specific regional analysis system for AD, which targets the volume of interest (VOI) in medial temporal structures, including the whole hippocampus, entorhinal cortex and amygdala. Results CSF levels of anti-Aβ autoantibodies were inversely correlated with the extent and severity of VOI atrophy, and the ratio of VOI/grey matter atrophy in patients with AD, but not in MCI or non-AD patients. Serum levels of anti-Aβ autoantibodies were not associated with these parameters in any of the patient groups. Conclusions These results indicate that CSF levels of naturally occurring anti-Aβ autoantibodies are inversely associated with the degree of the VOI atrophy in patients with AD. Although the mechanism is unclear, CSF levels of naturally occurring anti-Aβ autoantibodies may be implicated in the progression of atrophy of the whole hippocampus, entorhinal cortex and amygdala, in AD.

UR - http://www.scopus.com/inward/record.url?scp=84977565362&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977565362&partnerID=8YFLogxK

U2 - 10.1136/jnnp-2016-313476

DO - 10.1136/jnnp-2016-313476

M3 - Article

VL - 88

SP - 126

EP - 131

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 2

ER -